9 Einträge gefunden

1. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

   1. Facon, Thierry
   2. Cook, Gordon
   3. Usmani, Saad Z
   4. Hulin, Cyrille
   5. Kumar, Shaji
   6. Plesner, Torben
   7. Touzeau, Cyrille

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

   1. Cavo, Michele
   2. San-Miguel, Jesus F F
   3. Usmani, Saad Z
   4. Weisel, Katja C
   5. Dimopoulos, Meletios A A
   6. Avet-Loiseau, Hervé
   7. Paiva, Bruno

   2022 - Forschungsinformationssystem des UKE
3. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

   1. Davies, Faith E
   2. Pawlyn, Charlotte
   3. Usmani, Saad Z
   4. San-Miguel, Jesus F
   5. Einsele, Hermann
   6. Boyle, Eileen M
   7. Corre, Jill

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

   1. Quach, Hang
   2. Nooka, Ajay
   3. Samoylova, Olga
   4. Venner, Christopher P
   5. Kim, Kihyun
   6. Facon, Thierry
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

   1. Perrot, Aurore
   2. Facon, Thierry
   3. Plesner, Torben
   4. Usmani, Saad Z
   5. Kumar, Shaji
   6. Bahlis, Nizar J
   7. Hulin, Cyrille

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

   1. Avet-Loiseau, Hervé
   2. San-Miguel, Jesus
   3. Casneuf, Tineke
   4. Iida, Shinsuke
   5. Lonial, Sagar
   6. Usmani, Saad Z
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

   1. Mateos, Maria-Victoria
   2. Spencer, Andrew
   3. Nooka, Ajay K
   4. Pour, Ludek
   5. Weisel, Katja
   6. Cavo, Michele
   7. Laubach, Jacob P

   2020 - Forschungsinformationssystem des UKE
8. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

   1. Dimopoulos, Meletios
   2. Quach, Hang
   3. Mateos, Maria-Victoria
   4. Landgren, Ola
   5. Leleu, Xavier
   6. Siegel, David
   7. Weisel, Katja

   2020 - Forschungsinformationssystem des UKE
9. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

   1. Costello, Caitlin
   2. Davies, Faith E
   3. Cook, Gordon
   4. Vela-Ojeda, Jorge
   5. Omel, Jim
   6. Rifkin, Robert M
   7. Berdeja, Jesus

   2019 - Forschungsinformationssystem des UKE